QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=9066F83F093952A2C700D8AE88761875;jsessionid=70C337FB850E2377A18046555C2E2777;jsessionid=B2DFAF4BA4791C0AFC96402E36985551;jsessionid=A7A88901BCA75BFDA78052588D626E5C;jsessionid=EA57B8A1E5CD29CEBBC027C038437ECB;jsessionid=2C2CCEC93E609082D048123B5F356EC8;jsessionid=1C6AFE661E0A2ACD1F4831C8BA1369DF;jsessionid=A5DCB84F41D8EF5C9F66ACE2F8419C90 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. Abnormal open states patterns in the ATXN2 DNA sequence depends on the CAG repeats length.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=9066F83F093952A2C700D8AE88761875;jsessionid=70C337FB850E2377A18046555C2E2777;jsessionid=B2DFAF4BA4791C0AFC96402E36985551;jsessionid=A7A88901BCA75BFDA78052588D626E5C;jsessionid=EA57B8A1E5CD29CEBBC027C038437ECB;jsessionid=2C2CCEC93E609082D048123B5F356EC8;jsessionid=1C6AFE661E0A2ACD1F4831C8BA1369DF;jsessionid=A5DCB84F41D8EF5C9F66ACE2F8419C90